Tarlatamab injection for advanced small cell lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called tarlatamab, given as an injection under the skin (like a shot), for people with advanced small cell lung cancer that has worsened after chemotherapy. The goal is to see if this treatment can help shrink or slow down the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You have extensive-stage small cell lung cancer that has grown or returned after at least one round of platinum chemotherapy.
- You are generally active and able to care for yourself (ECOG 0 or 1).
- Your major organs (heart, lungs, kidneys, liver) are working well enough.
- You can receive injections in your belly (abdomen).
- You have not had treatment before that targets DLL3.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two drugs, tarlatamab and AB248, for people with extensive stage small cell lung cancer that has worsened after at least one prior treatment. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests adding a new immunotherapy drug (tarlatamab) to the standard first-line chemo-immunotherapy for extensive-stage small cell lung cancer. It aims to see if the combination works better than the usual treatment alone.
This trial tests a drug called tarlatamab for people with advanced prostate cancer that has a specific protein (DLL3) on their tumor cells. The goal is to see if tarlatamab can help shrink or slow the cancer.
This trial tests a new drug called tarlatamab, given either as an injection under the skin or through an IV, for people with extensive-stage small cell lung cancer that has grown or come back after one round of chemotherapy. The goal is to see which way of giving the drug works better and is safer.
This trial tests an experimental drug called tarlatamab for people newly diagnosed with extensive-stage small-cell lung cancer (SCLC). The goal is to see if tarlatamab can help shrink or control the cancer.
This trial tests a new drug called tarlatamab for people with advanced small cell lung cancer that has worsened after one prior round of chemotherapy plus immunotherapy. It's designed for patients who are still active but may need extra support (ECOG 2).
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.